Results 51 to 60 of about 933,739 (304)
Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro +6 more
wiley +1 more source
Combination Chemotherapy in Severe Pulmonary Vein Stenosis—A Case Series
, 2023 Pulmonary vein stenosis results from a proliferative process that leads to the progressive obstruction of venous return to the left atrium. It is often resistant to catheterization and surgical based interventions and is frequently fatal when encountered
David Nykanen +5 more
core +1 more source
Venous Thromboembolism in Denmark: Seasonality in Occurrence and Mortality
TH Open, 2019 Background Many cardiovascular conditions exhibit seasonality in occurrence and mortality, but little is known about the seasonality of venous thromboembolism.
Nils Skajaa +5 more
doaj +1 more source
Management of Tetralogy of Fallot with Pulmonary Atresia [PDF]
, 2005 Tetralogy of Fallot with Pulmonary Atresia is an extreme form of tetralogy characterized by absence of flow from the right ventricle to the pulmonary arteries.
Prieto, Lourdes R.
core
Losartan ameliorates “upstream” pulmonary vein vasculopathy in a piglet model of pulmonary vein stenosis [PDF]
, 2014 ObjectivesPulmonary vein stenosis (PVS) is a relentless disease with a poor prognosis. Although surgical repair can effectively treat “downstream” (near left atrial junction) PVS, residual “upstream” (deep in lung parenchyma) PVS commonly dictates long ...
Fu, Yaqin Yana +8 more
core +1 more source
Pulmonary Vein Stenosis: A Rare Disease with a Global Reach
, 2021 Pulmonary vein stenosis (PVS) is a rare, but high mortality and resource intensive disease caused by mechanical obstruction or intraluminal myofibroproliferation, which can be post-surgical or idiopathic.
Jennifer Schramm +6 more
core +1 more source
Arthritis Care &Research, EarlyView.Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato +27 more
wiley +1 more source
Respirology Case ReportsCongenital pulmonary vein atresia (PVA) is a rare condition often associated with vascular anomalies and complex pulmonary hemodynamics. A 54‐year‐old woman was referred for evaluation of a nodular shadow in the right upper lobe, initially suspected to ...
Takahiro Arano +9 more
doaj +1 more source
, 2023 Background:Dirofilaria immitis produces proliferative pulmonary endarteritis and pulmonary thromboembolism in infected dogs. The pulmonary vascular lesions lead to irreversible and persistent structural damage and, as a consequence, sustained ...
García-Rodríguez, Sara Nieves +13 more
core +1 more source
The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases
Arthritis Care &Research, EarlyView.Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci +25 more
wiley +1 more source